Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

HOUSTON, February 08, 2022 (GLOBE NEWSWIRE) — Therapeutic markerInc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focused on developing next-generation T-cell immunotherapies for the treatment of hematological malignancies and solid tumor indications, announced today today that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company’s clinical programs, manufacturing processes and pipeline.

The webcast will be accessible in the Investors section of the Company’s website at www.markertherapeutics.com. Individuals may participate in the conference call by dialing 877-869-3847 (domestic) or 201-689-8261 (international) and referring to the “Marker Therapeutics Clinical Program Update Call”.

The archived webcast will be available for replay on Marker’s website after the event.

On Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of unmodified tumor-specific T cells that recognize tumor-associated antigens (i.e. tumor targets) and kill tumor cells expressing these targets. This population of T cells is designed to attack multiple tumor targets after infusion into patients and to activate the patient’s immune system to produce broad-spectrum antitumor activity. Since Marker does not genetically modify its T-cell therapies, we believe that our product candidates will be easier and cheaper to manufacture, with reduced toxicities, compared to current CAR-T and TCR-based approaches, and can provide patients with meaningful clinical results. advantage. As a result, Marker believes its portfolio of T cell therapies has a compelling product profile, compared to current CAR-T and genetically engineered TCR therapies.

To receive future press releases by email, please visit: https://www.markertherapeutics.com/email-alerts.

IR and media contacts

Therapeutic marker:

Neda SafarzadehVice President/Head of Investor Relations, Public Relations and Marketing
(713) 400-6451
[email protected]

Solebury Trout:

InvestorsXuan Yang[email protected]

MediaAmy Bonanno[email protected]

main logo

Source: Therapeutic marker

2022 GlobeNewswire, Inc., source Press Releases

Michael P. Boser